The lowest diagnosed prevalent population of Retinitis Pigmentosa was recorded in Spain.Īs per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for males, in comparison to females, except in Japan, where females occupy a larger patient pool than males. In 2017, Japan had 28,000+ prevalent cases of Retinitis Pigmentosa.Īmong the 7MM, the most diagnosed prevalent cases of Retinitis Pigmentosa were recorded in the United States. The estimates show that in 2017, the diagnosed prevalence of Retinitis Pigmentosa in the United States was 108,700+. In 2017, the diagnosed Retinitis Pigmentosa prevalent population in the 7MM was 253,400+.Īmong the European 5 countries, Germany had the highest diagnosed prevalent population of Retinitis Pigmentosa with 30,600+ cases, followed by France and the United Kingdom with 27,800+ and 23,100+ cases, respectively. The way RP is passed from generation to generation can tell you who in the family has had the condition, how severely the vision could be affected, and the chances of the children being affected. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness.Īs per the secondary analysis, about half of people with RP have another family member with the condition. Most forms of RP first cause the breakdown of rod cells. RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Retinitis Pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. The Retinitis Pigmentosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. Some of the key factors, such as the expected launch of potential therapies, along with increasing awareness and ongoing Research and Development (R&D) activities by the global pharma and biotech giants in the therapeutic segment, will drive the Retinitis Pigmentosa Market growth.ĭelveInsight’s “ Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Retinitis Pigmentosa Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). As per DelveInsight, the Retinitis Pigmentosa Market size was found to be USD 237.27 million in 2017, which is expected to increase in the coming years.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |